Open Account
Demo Account
About Us
Real-time Quotes & News
Market Analysis
Economic Calendar
Daily Market Analysis
Trading Platform
Platform Overview
How To Use
Terms
All Terms
Deposit & Withdrawal
Promotion
FAQ
Contact
繁
简
EN
User Login
Open Account
Demo Account
繁
简
EN
User Login
Open Account
Demo Account
About Us
About Aspire
Features of Aspire
Real-time Quotes & News
Real-time Quotes
Real-time News
Market Analysis
Economic Calendar
Market Analysis
Trading Platform
Meta Trader 5
Platform Features
Terms
All Terms
Deposit & Withdrawal
Promotion
FAQ
Contact
About Us
Terms
Metals Market
Trading Platform
Market Analysis
Promotion
FAQ
Contact
繁
简
EN
Japanese chip stocks surged, with SoftBank Group shares rising 6.8%, Ibiden up 14%, and Kioxia up 3.7%.
2026-09-24
Japanese chip stocks surged, with SoftBank Group shares rising 6.8%, Ibiden up 14%, and Kioxia up 3.7%.
Back
Other News
2026-09-23
CENTCOM said it is assembling the world’s first multinational joint attack unmanned aerial systems (UAS) force. The command said its Rapidly Deployable Joint Task Force (REJTF), stood up one year ago, has introduced advanced capabilities including th
CENTCOM said it is assembling the world’s first multinational joint attack unmanned aerial systems (UAS) force. The command said its Rapidly Deployable Joint Task Force (REJTF), stood up one year ago, has introduced advanced capabilities including the US military’s first one-way attack UAS squadron in the Middle East and the first sea-launched air-attack UAS from a US Navy vessel. In June an unmanned surface vessel (USV) assisted in rescuing a downed helicopter crew in regional waters; in July CENTCOM recorded the first operational use of a one-way attack USV. The multinational force is presented as a follow-on to those operational advances over the past 52 weeks.
2026-09-24
Guojin Securities notes at the 2026 WCLC in Seoul Chinese innovative drugs featured prominently: Akeso’s Yiwoxi showed head-to-head superiority to pembrolizumab in first-line NSCLC; PD‑1/VEGF bispecifics are emerging as leaders in IO 2.0; B7‑H3 ADCs
Guojin Securities notes at the 2026 WCLC in Seoul Chinese innovative drugs featured prominently: Akeso’s Yiwoxi showed head-to-head superiority to pembrolizumab in first-line NSCLC; PD‑1/VEGF bispecifics are emerging as leaders in IO 2.0; B7‑H3 ADCs advanced to plenary sessions and ADC programs are pushing into frontline and perioperative use. Precision therapies targeting KRAS G12D, HER2 and EGFR resistance also posted clinical progress. The research note concludes Chinese bispecifics, ADCs and oligonucleotide candidates are globally competitive with leading data and could catalyze a new wave of outbound commercialization and sector valuation rerating.
Chat with us
, powered by
LiveChat